KMID : 0923620100100030104
|
|
Immune Network 2010 Volume.10 No. 3 p.104 ~ p.108
|
|
Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11b+Gr-1+ Myeloid-derived Suppressor Cells
|
|
Lee Jung-Mi
Seo Jeong-Hwan Kim Yeon-Jeong Kim Yun-Sun Ko Hyun-Jeong Kang Chang-Yuil
|
|
Abstract
|
|
|
CD137 (4-1BB/tnfrsf9) has been shown to co-stimulate T cells. However, agonistic anti-CD137 monoclonal antibody (mAb) treatment can suppress CD4+ T cells, ameliorating autoimmune diseases, whereas it induces activation of CD8+ T cells, resulting in diverse therapeutic activity in cancer, viral infection. To investigate the CD137-mediated T cell suppression mechanism, we examined whether anti-CD137 mAb treatment could affect CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs). Intriguingly, anti-CD137 mAb injection significantly increased CD11b+Gr-1+ cells, peaking at days 5 to 10 and continuing for at least 25 days. Furthermore, this cell population could suppress both CD8+ T cells and CD4+ T cells. Thus, this study demonstrated that, for the first time, anti-CD137 mAb treatment could induce CD11b+Gr-1+ MDSCs under normal conditions, suggesting a possible relationship between myeloid cell induction and CD137-mediated immune suppression.
|
|
KEYWORD
|
|
CD137, CD11b+Gr-1+ cells, Myeloid-derived suppressor cells, Immunosuppression
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|